Shop Medications , Common GLP1-s include: Semaglutide (Ozempic, Wegovy, Rybelsus) from Novo Nordisk Tirzepatide (Mounjaro, Zepbound dual GLP-1/GIP) from Eli Lilly Liraglutide (Saxenda, Victoza) from Novo Nordisk Orforgliprofin (Foundayo) from Eli Lilly These medications help regulate blood sugar, reduce appetite, and support long-term weight loss, which can also reduce the risk of serious complications
Consulting with healthcare providers ensures safe and effective use of GLP-1 therapies for diabetes and obesity management.
Lower estrogen, reduced activity over time, and menopause-related sleep disruption often work together to drive steady weight gainabout 1.5 pounds per year on average after menopause
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us
Current head-to-head evidence suggests tirzepatide may produce greater average weight loss than semaglutide